These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 2395115)

  • 21. Antagonist-induced opioid receptor up-regulation. I. Characterization of supersensitivity to selective mu and kappa agonists.
    Millan MJ; Morris BJ; Herz A
    J Pharmacol Exp Ther; 1988 Nov; 247(2):721-8. PubMed ID: 2846827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of opioid analgesia by agmatine.
    Kolesnikov Y; Jain S; Pasternak GW
    Eur J Pharmacol; 1996 Jan; 296(1):17-22. PubMed ID: 8720472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [D-Pro10]-dynorphin(1-11) is a kappa-selective opioid analgesic in mice.
    Gairin JE; Gout R; Meunier JC; Cros J
    J Pharmacol Exp Ther; 1988 Jun; 245(3):995-1001. PubMed ID: 2898527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
    Millan MJ; Członkowski A; Lipkowski A; Herz A
    J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism.
    Jiang Q; Seyed-Mozaffari A; Sebastian A; Archer S; Bidlack JM
    J Pharmacol Exp Ther; 1995 May; 273(2):680-8. PubMed ID: 7752070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Examination of the involvement of supraspinal and spinal mu and delta opioid receptors in analgesia using the mu receptor deficient CXBK mouse.
    Vaught JL; Mathiasen JR; Raffa RB
    J Pharmacol Exp Ther; 1988 Apr; 245(1):13-6. PubMed ID: 2834533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerance to morphine bradycardia in the rat.
    Kiang JG; Dewey WL; Wei ET
    J Pharmacol Exp Ther; 1983 Jul; 226(1):187-91. PubMed ID: 6864538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serotonergic involvement in the antinociceptive action of and the development of tolerance to the kappa-opioid receptor agonist, U-50, 488H.
    Ho BY; Takemori AE
    J Pharmacol Exp Ther; 1989 Aug; 250(2):508-14. PubMed ID: 2547935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
    Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
    J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The ontogeny of mu opiate tolerance and dependence in the rat: antinociceptive and biochemical studies.
    Windh RT; Little PJ; Kuhn CM
    J Pharmacol Exp Ther; 1995 Jun; 273(3):1361-74. PubMed ID: 7791109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sites of antinociceptive action of systemically injected morphine: involvement of supraspinal loci as revealed by intracerebroventricular injection of naloxone.
    Yeung JC; Rudy TA
    J Pharmacol Exp Ther; 1980 Dec; 215(3):626-32. PubMed ID: 7441522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A characterization of the antinociception produced by intracerebroventricular injection of 8-(N,N-diethylamino)octyl-3,4,5-trimethoxybenzoate in mice.
    Welch SP; Dewey WL
    J Pharmacol Exp Ther; 1986 Nov; 239(2):320-6. PubMed ID: 3095536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cross-tolerance between mu- and kappa-opioid agonists in the guinea pig ileum myenteric plexus.
    Garaulet JV; Laorden ML; Milanés MV
    J Pharmacol Exp Ther; 1994 Jun; 269(3):993-9. PubMed ID: 8014886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhancement of morphine antinociception by a CCKB antagonist in mice is mediated via opioid delta receptors.
    Vanderah TW; Bernstein RN; Yamamura HI; Hruby VJ; Porreca F
    J Pharmacol Exp Ther; 1996 Jul; 278(1):212-9. PubMed ID: 8764354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Opioid modulation of fetal glucose homeostasis: role of receptor subtypes.
    Szeto HH; Soong Y; Wu DL; Cheng PY
    J Pharmacol Exp Ther; 1995 Oct; 275(1):334-9. PubMed ID: 7562568
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Supraspinally administered agmatine prevents the development of supraspinal morphine analgesic tolerance.
    Kitto KF; Fairbanks CA
    Eur J Pharmacol; 2006 Apr; 536(1-2):133-7. PubMed ID: 16546161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced naloxone distribution to the brain by morphine pretreatment in mice.
    Lange DG; Fujimoto JM; Roerig S; Wang RI
    Drug Metab Dispos; 1977; 5(2):167-73. PubMed ID: 15809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peripheral morphine analgesia: synergy with central sites and a target of morphine tolerance.
    Kolesnikov YA; Jain S; Wilson R; Pasternak GW
    J Pharmacol Exp Ther; 1996 Nov; 279(2):502-6. PubMed ID: 8930151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Motility effects of methamphetamine in morphine-tolerant mice by the DAP method].
    Suzuki T; Yoshii T; Kawai T; Yanaura S
    Nihon Yakurigaku Zasshi; 1984 Mar; 83(3):249-54. PubMed ID: 6724432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerance to morphine analgesia: decreased multiplicative interaction between spinal and supraspinal sites.
    Roerig SC; O'Brien SM; Fujimoto JM; Wilcox GL
    Brain Res; 1984 Aug; 308(2):360-3. PubMed ID: 6548169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.